1. Analyzing microsatellite instability and gene mutation in circulating cell-free DNA to monitor colorectal cancer progression
- Author
-
Hongmei Wu, Xiaorong Liu, Yuedian Ye, Yangwei Xu, Guifang Zhu, Shanshan Jiang, Feiyan Feng, Yun Fu, Yanyan Li, Zhihui Wen, Jingbo Sun, and Qingling Zhang
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,Cancer Research ,microsatellite instability (MSI) ,Colorectal cancer ,business.industry ,Microsatellite instability ,Gene mutation ,medicine.disease ,digestive system diseases ,circulating cell-free DNA (cfDNA) ,Circulating Cell-Free DNA ,Colorectal cancer (CRC) ,Oncology ,medicine ,Cancer research ,Original Article ,Radiology, Nuclear Medicine and imaging ,gene mutation ,next-generation sequencing (NGS) ,business ,neoplasms - Abstract
Background Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. Detection of microsatellite instability (MSI) status and gene mutations may be useful for molecular targeted therapy. The liquid biopsy is a newly developed, non-invasive method for tumor diagnosis and monitoring. In this study, we evaluated the possible clinical value of liquid biopsy by analyzing MSI and gene mutation. Methods Next-generation sequencing (NGS) was used to analyze MSI and gene mutation in circulating cell-free DNA (cfDNA) and tissue DNA extracted from 6 CRC patients’ plasma and matched primary tumor tissue (MPTT) samples, respectively. Results A total of 6 patients (4 male, 2 female) were included for analysis, whose stage ranges from stage I through stage III. NGS-based panel of 5 quasi-monomorphic microsatellite markers (MSI-NGS) BAT-25, BAT-26, NR21, NR24 as well as NR27, and 4 mismatch repair (MMR) genes (MSH2, MSH6, PMS2, MLH1) expressions assessed by immunohistochemistry (MMR-IHC) and NGS (MMR-NGS) were used to determine MSI status synergistically. Comprehensive analysis of NGS and IHC results showed that the overall incidences of MSI in plasma and MPTT samples from these patients were 1/6 and 2/6, respectively. 4 patients were defined as microsatellite stable (MSS) in both plasma and MPTT. In the above 6 patients, MSI-NGS detection in cfDNA accurately identified 1/2 of tissue high-level microsatellite instability (MSI-H) and 4/4 of tissue MSS for an overall accuracy of 5/6. Gene mutational profiles in these CRC patients’ plasma and MPTT samples were analyzed by NGS. Tumor-specific gene mutations were detected in 2/6 of plasma and 4/4 of MPTT samples. The two mutation-positive plasma samples were from CRC patients at stage IIb and stage IIIc. Conclusions Analyzing MSI and gene mutation might be a non-invasive supplementary way to reveal the molecular characteristics of CRC.
- Published
- 2021